Psychedelic therapies remain controversial in some parts of the Hem/Onc Pharmacy space, but are beginning to enter the mainstream. It’s an area of cancer care that remains shrouded in misconception, but it might offer patients, caregivers and the bereaved exactly what they need if it is increasingly accepted and more effectively regulated on a wider scale.  

Ben and Matt are joined by a panel of experts to discuss the opportunities, risks, and challenges of psychedelic therapies in cancer care. Paul Hutson; Andrew Whitman, PharmD, BCOP; and Kelan Thomas share some fascinating insights into why microdosing is problematic; drug-drug interactions; potential therapy for those suffering from chronic grief; socioeconomic inequities in access and usage; as well as assessing portrayals in popular culture. 

Learn more about the Psychedelic Pharmacists Association, including how to become a member: https://psychedelicpharmacist.org/  

Find out about any upcoming psychedelics clinical trials through the NIH’s website:  https://clinicaltrials.gov/  

Learn more about Oregon and Colorado’s Psilocybin practices, respectively, through their official state health authority websites: https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx (Oregon) 

https://dpo.colorado.gov/NaturalMedicine (Colorado) 

Interested in contributing to a future episode? Got a topic suggestion? We'd love to hear from you. Email us at communications@hoparx.org